SAHMI: Microbiome-based screening method for cancer and other diseases

​ ​ Screening methodology and principle data identifying differences in microbiome diversity from disease state in pancreatic cancer Invention Summary: The microbiome plays an essential role in the prognosis and progression of disease…
Screening methodology and principle data identifying differences in
microbiome diversity from a disease state in pancreatic cancer

Invention Summary:

The microbiome plays an essential role in the prognosis and progression of disease and health, as seen in cancers like pancreatic cancer. Pancreatic cancer is rising in the majority of cancer deaths and remains difficult to study with its large fibrotic tumor volume that hinders sampling and cellular mechanistic studies by existing bulk profiling methods. With increasing interest in using the microbiome for the treatment of disease, current methods remain non-specific in identifying tumor-microbiome interactions. There are currently no resources to thoroughly identify microbial associations at a more specific single-cell resolution for the prediction of disease and survival in tumor microenvironments.

Rutgers researchers have developed and utilized a systematic approach to quantifying and separating the microbiome using single-cell sequencing data and analyzing tumor-microbiome interactions at a single-cell resolution. The novel analytical framework, SAHMI (Single-cell Analysis of Host-Microbiome Interactions), was developed to identify differences between human pancreatic ductal adenocarcinomas and control tissue. This method identifies microbial diversity in disease versus control, microbiome-tumor co-evolution, an association of cell-type-specific pathways with the tumor microenvironment, patient-specific tumor phenotype, and can predict patient survival. Through pinpointing specific patterns in the microbiome associated with cell signaling and disease in high resolution, this invention can identify these patterns for diagnosis of disease and target for treatment.

Advantages:

  • Single-cell resolution using single-cell RNA sequencing technologies
  • Unbiased analysis of microbe-to-cellular pathway interactions with the whole microbiome
  • Higher resolution than current technologies, targeting 1/10 the size of eukaryotic cells

Market Applications:

  • Microbiome-based diagnostic tests for cancer and other diseases
  • Biomarker and drug discovery screening method using the microbiome

Intellectual Property & Development Status: Patent pending. Available for licensing and/or research collaboration.

Website

https://techfinder.rutgers.edu/tech?title=SAHMI%3a_Microbiome-based_screening_method_for_cancer_and_other_diseases

Contact Information

TTO Home Page: https://techfinder.rutgers.edu

Name: Tania Das Banerjee

Title: Licensing Manager

Department: Innovation Ventures

Email: td255@research.rutgers.edu